July 24, 2023

Arca trims losses as leaders continue mulling merger options

BOULDER — Pre-revenue pharmaceutical firm Arca Biopharma Inc. (Nasdaq: ABIO) continued cutting costs in the second quarter of 2023, while company leaders have still yet to announce whether the company will be acquired or merged with another operator. 

Arca — which has two drugs in its pipeline: COVID-19 drug candidate rNAPc2 and Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that could be a potential treatment for atrial fibrillation in heart-failure patients — established a committee to weigh options for maximizing shareholder value amid a 2021 that saw it double its year-over-year losses. 

Consulting firm…

Lucas is an award-winning journalist who worked at news agencies from Maryland to Wyoming to South Carolina before putting roots down in Colorado.

Related Posts

Sign up for BizWest Daily Alerts
Closing in 8 seconds...